Treatment of inflammatory bowel disease (IBD) in dogs and cats

• Autorzy: Malewska K. , Rychlik A. , Nieradka R. , Kander M.
• Języki publikacji: EN

Abstrakty

EN

The treatment of inflammatory bowel disease (IBD) possesses numerous difficulties owing to the unclear etiology of the disease. This article overviews the drugs used in the treatment of IBD depending on the intensity of clinical symptoms (Canine Inflammatory Bowel Disease Activity Index and Canine Chronic Enterophaty Clinical Activity Index). Patients demonstrating mild symptoms of the disease are usually placed on an appropriate diet which may be combined with immunomodulative or probiotic treatment. In moderate progression of IBD, 5-aminosalicylic acid (mesalazine or olsalazine) derivatives may be administered. Patients showing severe symptoms of the disease are usually treated with immunosuppressive drugs, antibiotics and elimination diet. Since the immune system plays an important role in the pathogenesis of the disease, the advancements in biological therapy research will contribute to the progress in the treatment of canine and feline IBD in the coming years.

Słowa kluczowe

EN

treatment; inflammatory bowel disease; dog; cat; animal disease; pathogenesis

• Wydawca: -
• Czasopismo: Polish Journal of Veterinary Sciences
• Rocznik: 2011
• Tom: 14
• Numer: 1
• Opis fizyczny: p.165-170,ref.

Twórcy

autor

Malewska K.

• Faculty of Veterinary Medicine, Department of Clinical Diagnostics, University of Warmia and Mazury in Olsztyn, Oczapowskiego 14, 10-719 Olsztyn-Kortowo, Poland

autor

Rychlik A.

autor

Nieradka R.

autor

Kander M.

Bibliografia

• Allenspach K, Gaschen F (2003) Chronic intestinal diseases in the dog: a review. Schweiz Arch Tierheilkd 5: 209-219, 221-222.
• Allenspach K, Rufenacht S, Sauter S, Grone A, Steffan J, Strehlau G, Gaschen F (2006) Pharmacokinetics and Clinical Efficacy of Cyclosporine Treatment of Dogs with Steroid-Refractory Inflammatory Bowel Disease. J Vet Intern Med 20: 239-244.
• Allenspach K, Steiner JM, Shah BN, Berghoff N, Ruaux C, Williams DA, Blum J W, Gaschen F (2006) Evaluation of gastrointestinal permeability and mucosal absorptive capacity in dogs with chronic entheropathy. Am J Vet Res 67: 479-83.
• Allenspach K, Wieland B, Grone A, Gaschen F (2007) Chronic Entheropathies in Dogs: Evaluation of Risk Factors for Negative Outcome. J Vet Intern Med 21: 700-708.
• Bhatia V, Tandon RK (2005) Stress and the gastrointestinal tract. J Gastroenterol Hepatol 20: 332-339.
• Craven M, Simpson JW, Ridyard AE, Chandler ML (2004) Canine inflammatory bowel disease: retrospective analysis of diagnosis and outcome in 80 cases (1995-2002). J Small Anim Pract 45: 336-342.
• Chen J, Seviour R (2007) Medicinal importance of fungal β-(1→3),(1→6) glucans. Mycol Res 3: 635-652.
• Chrząstowska M, Kander M, Depta A (2009) Prospects for the use of probiotic bacteria in the treatment of gastrointestinal diseases in dogs. Pol J Vet Sci 12: 279-284.
• Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G (2002) Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res 46: 1-6.
• Day MJ, Blizer T, Mansell J, Wilcock B, Hall EJ, Jergens A, Minami T, Willard M, Washabau R (2008) Histopathological Standards for the Diagnosis of Gastrointestinal Inflammation in Endoscopic Biopsy Samples from the Dog and Cat: A Report from the World Small Animal Veterinary Association Gastrointestinal Standardization Group. J Comp Pathol 138: S1-S43.
• Day M J (2004) Immunomodulatory therapy. Veterinary Dermatology 15: 1-19.
• Dennis JS, Kruger JM, Mullaney TP (1992) Lymphocytic/plasmacytic gastroenteritis in cats: 14 cases (1985-1990). J Am Vet Med Assoc 200: 1712-1718.
• Dennis JS, Kruger JM, Mullaney TP (1993) Lymphocytic/plasmacytic colitis in cats: 14 cases (1985-1990). J Am Vet Med Assoc 202: 313-318.
• Dossin O (2009) Chronic diarrhea in cats. Veterinary Focus 19: 2-9.
• Elliott D A (2006) Nutritional Considerations for the Gastrointestinal Patient. Bull Acad Vet France 159: 343-348.
• Garcia-Sancho M, Rodriguez-Franco F, Sainz A, Mancho C, Rodriguez A (2007) Evaluation of Clinical, Macroscopic, and Histopathologic Response to Treatment in Nonhypoproteinemic Dogs with Lymphocytic-Plasmacytic Enteritis. J Vet Intern Med 21: 11-17.
• Garside P (1999) Cytokines in experimental colitis. Clin Exp Immunol 118: 337-339.
• German AJ, Hall EJ, Day MJ (2003) Chronic Intestinal Inflammation and Intestinal Disease In Dogs. J Vet Intern Med 17: 8-20.
• German AJ, Hall EJ, Day MJ (2001) Immune cell populations within the duodenal mucosa of dogs with entheropathies. J Vet Intern Med 15: 14-25.
• German AJ, Helps CR, Hall EJ, Day MJ (2000) Cytokine mRNA Expression in Mucosal Biopsies from German Shepherd Dogs with Small Intestinal Enteropathies. Dig Dis Sci 45: 7-17.
• Ghosh S, van Heel D, Playford RJ (2003) Probiotics in inflammatory bowel disease: is it all gut flora modulation?. Gut 53: 620-622.
• Hall E J, German A J (2005) Disease of the Small Intestine. In: Ettinger SJ and Feldman EC (eds) Textbook of veterinary internal medicine, Elsevier, Philadelphia 1332-1340.
• Hall E J (2007) Mucosal Immunology- Why It’s Important; Immune-Mediated Intestinal Disease. Proceedings of the 32nd Annual WSAVA Congress. Sydney. 19-23. 08. 2007. http://www.vin.com/proceedings/Proceedings.plx?&CID =WSAVA2007&PID=pr18137&O=Generic
• Hiss S, Sauerwein H (2003) Influence of dietary β-glucan on growth performance, lymphocyte proliferation, specific immune response and haptoglobin plasma concentrations in pigs. J Anim Physiol Anim Nutr 87: 2-11.
• Hunter KW Jr., Gault RA, Berner MD (2002) Preparation of microparticulate β-glucan from saccharomyces cerevisiae for use in immune potentiation. Lett Appl Microbiol 35: 267-271.
• Jergens AE, Crandell J , Morrison JA, Deitz K, Pressel M, Ackermann M, Suchodolski JS, Steiner JM, Evans R (2010) Comparison o oral prednisone and prednisone combined with metronidazole for induction therapy of
• canine inflammatory bowel disease: a randomized-controlled trial. J Vet Intern Med 24: 269-277.
• Jergens AE, Schreiner CA, Frank DE, Niyo Y, Ahrens FE, Eckersall PD, Benson TJ, Evans R (2003) A scoring index for disease activity in canine inflammatory bowel disease. J Vet Intern Med 17: 291-297.
• Jergens AE (2002a) Understanding gastrointestinal inflammation-implications for therapy. J Feline Med Surg 4: 179-182.
• Jergens AE (2002b) Inflammatory bowel disease in the dog and cat. Proceedings of the 27th WSAVA Congress. Grenada, 08. 2002, pp 3-5. http://www.vin.com/proceedings/Proceedings.plx?CID=WSAVA2002&PID=2585
• Jergens AE (1999) Inflammatory bowel disease: Current perspectives. Vet Clin North Am Small Anim Pract 29: 501-521.
• Kurtovic J, Segal I (2004) Recent advances in biological therapy for inflammatory bowel disease. Trop Gastroenterol 25: 9-14.
• Li J, Xing J, Li D, Wang X, Zahao L, Lv S, Huang D (2005) Effects of β-glucan extracted from Saccharomyces cerevisae on humoral and cellular immunity in weaned pig. Arch Anim Nutr 59: 303-312.
• Macpherson AJ, Harris NL (2004) Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 4: 478-485.
• McCann TM, Ridyard AE, Else RW, Simpson JW (2007) Evaluation of disease activity markers in dogs with idiopathic inflammatory bowel disease. J Small Anim Pract 48: 620-625.
• Mitsuyama K, Toyobaga M, Sata M (2002) Intestinal microflora as a therapeutic target in inflammatory bowel disease. J Gastroenterol 37: 73-77.
• Modigliani R (2000) Immunosuppressors for inflammatory bowel disease: how long is long enough? Inflamm Bowel Dis 6: 251-257.
• Münster M, Hörauf A, Bilzer T (2006) Assessment of disease severity and outcome of dietary, antibiotic and immunosuppressive interventions by use of the canine IBD activity index in 21 dogs with chronic inflammatory bowel disease. Berl Munch Tierarztl Wochenschr 119: 493-505.
• Pelizon AC, Kaneno R, Soares AM, Meira DA, Sartori A (2005) Immunomodulatory activities associated with β-glucan derived from Saccharomyces cerevisae. Physiol Res 54: 557-564.
• Ransford RA, Langman MJ (2002) Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut 51: 536-539.
• Rychlik A, Nieradka R, Depta A, Paluszewski A, Sarti K (2008) Efficacy of different treatment methods in dogs’ inflammatory bowel disease. Med Weter 64: 796-799.
• Rychlik A, Malewska K, Nieradka R, Depta A, Kander M (2009) Nowe aspekty terapii nieswoistych stanów zapalnych jelit u psów. Immunomodulatory naturalne i syntetyczne. Aktualne problemy w patologii psów i kotów. 1st ed. ISBN- 978-83-929472-6-4. Polanica, pp. 71-75.
• Salavaggione OE, Kidd L, Prondzinski JL, Szumalanski CL, Pankratz VS, Wang L, Trepanier L, Weinshilboum RM (2002) Canine red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics. Pharmacogenetics 12: 713-724.
• Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto-Furusho JK (2008) Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14: 4280-4288.
• Sandborn WJ, Targan SR (2002) Biologic therapy in inflammatory bowel disease. Gastroenterology 122: 1592-1608.
• Sauter SN, Allenspach K, Blum JW (2007) Cytokine mRNA abundance in intestinal biopsies from dogs with chronic diarrhea. Vet Med 52: 353-364.
• Sauter SN, Allenspach K, Gaschen F, Grone A, Ontsouka E, Blum JW (2005) Cytokine expression in an ex vivo culture system of duodenal samples from dogs with chronic enteropathies: modulation by probiotic bacteria. Domest Anim Endocrinol 29: 605-622.
• Siwicki AK, Skopińska-Różewska E (2003) Immunomodulacja – aktualny stan wiedzy. Rola immunomodulatorów pochodzenia naturalnego w zapobieganiu i leczeniu chorób. 1st ed. ISBN 83-87340-84-7 Medyk, Warszawa, pp. 7-14.
• Stewart A, Bolineck J (1997) The use of novel formulation of budesonide as an improved treatment over prednisone for inflammatory bowel disease. J Vet Jntern Med 11: 115.
• Swanson KS, Grieshop CM, Flickinger EA, Bauer LL, Healy HP, Dawson KA, Merchen NR, Fahey GC Jr (2002a) Supplemental fructooligosaccharides and mannanoligosaccharides influence immune function, ileal and total tract nutrientdigestibilities, microbial populations and concentrations of protein catabolites in the large bowel of dogs. J Nutr 132: 980-989.
• Swanson KS, Grieshop C M, Flickinger E A, Healy H P, Dawson K A, Merchen N R, Fahey GC Jr (2002b) Effects of supplemental fructooligosaccharides plus mannanoligosaccharides on immune function and ileal and fecal microbial populations in adult dogs. ArchTierer nahr 56: 309-318.
• Szymańska-Czerwińska M, Bednarek D (2008) Effect of prebiotics on immunological processes in animals. Med Weter 64: 262-264.
• Tumulty JW, Broussard JD, Steiner JM, Peterson ME, Williams DA (2004) Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. J Am Anim Hosp Assoc 40: 120-123.
• Wagner RD, Warner T, Roberts L, Farmer J, Balish E (1997) Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect. Immun 65: 3345-3351.
• Washabau RJ (2008) Summary of Findings and Reports of the WSAVA Gastrointestinal Standardization Group. The 33rd WSAVA Congress. Dublin. 20-24. 08. 2008, pp. 60-62.
• Wójcik R, Małaczewska J, Trapkowska S, Siwicki AK (2007) Influence of β-1,3/1,6-D-glucan on non-specific cellular defence mechanisms in lambs. Med Weter 63: 84-86.
• Xenoulis PG, Palculict B, Allenspach K, Steiner JM, Van House AM, Suchodolski JS (2008) Molecular-phylogenetic characterization of microbial communities imbalances in the small intestine of dogs with inflammatory bowel disease. FEMS Microbiol Ecol 66: 579-589.
• Zentek J, Marquart B, Pietrzak T (2002) Intestinal effects of mannanoligosaccharides, transgalactooligosaccharides, lactose and lactulose in dogs. J Nutr 132:1682S-1684S.